The recombinant hepatitis B virus surface (HBsAg) and core (HBCAg) virus like particles (VLPs) have the ability to serve as carriers of foreign B cell and CTL epitopes. Different approaches have been used to couple the target epitopes, like the insertion into the primary sequence of the VLP, covalent and noncovalent linkage. Particularly, the non-covalent linkage was used to develop the vaccine formulation Teravac against the human immunodeficiency virus type 1 (HIV-1). Teravac is an aggregate of the recombinant protein CR3 of HIV-1 and both HBV VLPs. Previous studies have shown that immunization of Teravac in mice induced a Th1 response with CD8+ T cells. However, because millions of people are infected with the HBV and millions of doses of the HBV vaccine have been administered worldwide, the pre-existing immune response to the HBV antigens is rather frequent event. This opens the question about the impact of the anti-HBc and/or anti-HBs antibody response on the CR3(HIV)-specific cellular response elicited with Teravac. To answer this question, the effect of the pre-existing anti-HBc and the combined anti-HBc/anti-HBs antibodies was studied in mice. Our findings suggest that the induction of CR3(HIV)-specific cellular responses of CD4+ and CD8+ cells are not impaired by pre-existing high IgG titters in either situation.

**Keywords:** HIV vaccines, cellular immune response, hepatitis B antibodies, hepatitis B core antigens, hepatitis B surface antigen

**ABSTRACT**

The recombinant hepatitis B virus surface (HBsAg) and core (HBCAg) virus like particles (VLPs) have the ability to serve as carriers of foreign B cell and CTL epitopes. Different approaches have been used to couple the target epitopes, like the insertion into the primary sequence of the VLP, covalent and noncovalent linkage. Particularly, the non-covalent linkage was used to develop the vaccine formulation Teravac against the human immunodeficiency virus type 1 (HIV-1). Teravac is an aggregate of the recombinant protein CR3 of HIV-1 and both HBV VLPs. Previous studies have shown that immunization of Teravac in mice induced a Th1 response with CD8+ T cells. However, because millions of people are infected with the HBV and millions of doses of the HBV vaccine have been administered worldwide, the pre-existing immune response to the HBV antigens is rather frequent event. This opens the question about the impact of the anti-HBc and/or anti-HBs antibody response on the CR3(HIV)-specific cellular response elicited with Teravac. To answer this question, the effect of the pre-existing anti-HBc and the combined anti-HBc/anti-HBs antibodies was studied in mice. Our findings suggest that the induction of CR3(HIV)-specific cellular responses of CD4+ and CD8+ cells are not impaired by pre-existing high IgG titters in either situation.

**Keywords:** HIV vaccines, cellular immune response, hepatitis B antibodies, hepatitis B core antigens, hepatitis B surface antigen

**RESUMEN**

La administración parenteral del candidato vacunal TERAVAC-HIV-1 no es interferida por la respuesta inmune previa contra antígenos del virus de la hepatitis B en ratones. Los antígenos recombinantes de superficie y de la cápsida del virus de la hepatitis B (HBsAg y HBCAg, respectivamente) estructurados como partículas similares a virus (VLP) sirven como portadores de epitopos de células B y linfocitos T citotóxicos heterólogos. Tales epitopos se acoplan mediante estrategias como la inserción en la secuencia primaria de las VLP, o mediante unión covalente o no covalente. Esta última se usó para desarrollar la formulación vacunal Teravac contra el virus de la inmunodeficiencia humana tipo 1 (VIH-1). Teravac es un agregado entre la proteina CR3 derivada del VIH-1 y las VLP de ambos antígenos del HBV. Estudios previos mostraron que la inmunización con Teravac en ratones indujo una respuesta de células T CD8+ de tipo Th1. Sin embargo, millones de personas son infectadas con el HBV y se han administrado millones de dosis vacunales contra este virus, con la frecuente inducción de respuesta inmune contra el HBCAg, el HBsAg o ambos. Con vistas a indagar sobre el posible impacto de la respuesta de anticuerpos anti-HBc, anti-HBs o ambas sobre la respuesta celular específica generada contra el antígeno CR3 al inmunizar con Teravac, se estudió el efecto de la respuesta pre-existente de anticuerpos anti-HBc y de su combinación con anticuerpos anti-HBs sobre la respuesta de linfocitos CD4+ y CD8+ en ratones. Nuestros resultados sugieren que la inducción de dicha respuesta celular contra el antígeno CR3 del VIH-1 no es interferida por los altos títulos de anticuerpos de subclase IgG generados con cualquiera de las variantes de VLP ensayadas.

**Palabras clave:** vacunas contra VIH, respuesta inmune celular, anticuerpos contra hepatitis B, antígeno de la cápsida de la hepatitis B, antígeno de superficie de la hepatitis B

**Introduction**

Success in controlling the viral load, and an impressive improvement in the quality of life and life expectancy, have been achieved with antiretroviral therapies in HIV+ patients [1]. But, in spite of the hypothetical impact on the prevention of transmission expected with the 90-90-90 strategy proposed by UNAIDS [2] and the prospect of success with the Prep, a huge number of limitations in the field have to be surmounted. Regarding to this, it is known that low and lower middle-income countries lack financial support and sanitary infrastructure to achieve long-term implementation of these programs [3]. That is why many scientists still consider vaccination as the best measure to control the pandemic [4, 5].

In line with the vaccination strategy, a multiantigenic vaccine candidate named Teravac was developed, to induce essentially an anti-HIV-1 cellular immune response. This formulation contains aggregates of the recombinant protein CR3 with the surface (HBsAg, S) and core (HBCAg, C) virus-like particles (VLPs) of the hepatitis B virus (HBV) [6, 7]. The CR3 protein is a subunit antigen comprising several T helper (Th) and cytotoxic T lymphocyte (CTL) rich regions of HIV-1 proteins. The HBV antigens allow an
Effect of anti-HBc and anti-HBs Abs on Teravac inoculation

305-25 mM sodium citrate, 1 mg/mL o-phenylenediamine, and 0.1 % H


Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what’s important Hum Vaccin Immunother. 2014;10(10):2875-84.


Materials and methods

Antigens

The entire recombinant (r)HBcAg particle of 183 amino acids was expressed in Escherichia coli and the HBsAg subtype adw2 in the yeast Pichia pastoris. The purification processes for both antigens were published [18, 19].

The HIV-1 antigen CR3 is composed of cytotoxic T lymphocyte (CTL) and helper T cell (Th) epitope-rich regions comprising T1 (Env(421-440), protein location in HBX2 isolate), T2 (Env(305-313)), and the V3 loop (Env(313-318)) from gp120, an epitope from gp41 (Env(643-649)), another from Vpr (Vpr(474-481)), a fragment of the p66/p51 (reverse transcriptase; RT) protein (Pol(191-212)), a part of Nef (Nef(309-318)), and a part of p24 Gag (Gag (99-105)). It was purified from E. coli Bl2.1-CodonPlus (DE3)-

RIL (Stratagene, La Jolla, CA) and the purification process was as described previously [6].

All antigens were pyrogen-free products with more than 95 % purity [6, 18, 19].

Immunizations

Four groups of 6-8-weeks-old female Balb/c mice, purchased from CENPALAB (Havana, Cuba), were immunized in two rounds as shown in figure 1. Pre-immune sera were obtained two days ahead of the immunizations. In the first phase, 12 animals per group were inoculated twice on days 0 and 13 with: groups 1 and 2, phosphate-buffered saline (PBS; placebo); 3, HBcAg (C) and 4, mixture of HBcAg and HBsAg (C+S). In the second phase, the animals received three additional inoculations on days 35, 56, and 77 with: group 1, Teravac (positive control); 2, C+S (negative control); 3, and 4, Teravac (experimental groups). In all cases immunogens were prepared a day before and stored at 4°C until inoculation. They were administered subcutaneously in a 100 μL volume, adjuvanted in 1 mg/mL aluminum hydroxide (AlOOH; Superfos Biosector A/S, Vedbaek, Denmark). The dose for all antigens was 5 μg/mouse.

The experiment and care of animals was conducted in accordance with institutional guidelines to avoid unnecessary suffering.

Serology

To assess the induction of anti-HBc and anti-HBs IgG-specific antibodies at the end of the phase 1, day 34 animals’ sera were tested by an indirect EIA as reported [8]. Briefly, high binding capacity 96-well plates (Corning Life Sciences, Acton, MA) were coated with the antigen at 5 μg/mL. Plates were blocked with 2 % skim milk in PBS for 1 h at 37 °C. Subsequently, they were incubated with serum samples diluted in 1 % skim milk, and 1 % Tween 20 in PBS for 2 h at 37 °C. Rabbit-anti-mouse total IgG-specific antibodies at the end of the phase 1, day 34 animals’ sera were tested by an indirect EIA as reported [8].

The antigen CR3 was administered combined with the virus like particles of C and S proteins, respectively, with antigens immunizations and bleedings established as represented.

Figure 1. Immunization regime for evaluating the effect of pre-existing antibody responses against the hepatitis B core (C) and surface (S) antigens on the cellular immune response against the CR3 antigen. The antigen CR3 was administered combined with the virus like particles of C and S proteins, as the TERAVAC HIV-1 vaccine candidate. Two immunization phases were established (phase I and II, respectively) with antigens immunizations and bleedings established as represented.

The experiment and care of animals was conducted in accordance with institutional guidelines to avoid unnecessary suffering.


Materials and methods

Antigens

The entire recombinant (r)HBcAg particle of 183 amino acids was expressed in Escherichia coli and the HBsAg subtype adw2 in the yeast Pichia pastoris. The purification processes for both antigens were published [18, 19].

The HIV-1 antigen CR3 is composed of cytotoxic T lymphocyte (CTL) and helper T cell (Th) epitope-rich regions comprising T1 (Env(421-440), protein location in HBX2 isolate), T2 (Env(305-313)), and the V3 loop (Env(313-318)) from gp120, an epitope from gp41 (Env(643-649)), another from Vpr (Vpr(474-481)), a fragment of the p66/p51 (reverse transcriptase; RT) protein (Pol(191-212)), a part of Nef (Nef(309-318)), and a part of p24 Gag (Gag (99-105)). It was purified from E. coli Bl2.1-CodonPlus (DE3)-

RIL (Stratagene, La Jolla, CA) and the purification process was as described previously [6].

All antigens were pyrogen-free products with more than 95 % purity [6, 18, 19].

Immunizations

Four groups of 6-8-weeks-old female Balb/c mice, purchased from CENPALAB (Havana, Cuba), were immunized in two rounds as shown in figure 1. Pre-immune sera were obtained two days ahead of the immunizations. In the first phase, 12 animals per group were inoculated twice on days 0 and 13 with: groups 1 and 2, phosphate-buffered saline (PBS; placebo); 3, HBcAg (C) and 4, mixture of HBcAg and HBsAg (C+S). In the second phase, the animals received three additional inoculations on days 35, 56, and 77 with: group 1, Teravac (positive control); 2, C+S (negative control); 3, and 4, Teravac (experimental groups). In all cases immunogens were prepared a day before and stored at 4°C until inoculation. They were administered subcutaneously in a 100 μL volume, adjuvanted in 1 mg/mL aluminum hydroxide (AlOOH; Superfos Biosector A/S, Vedbaek, Denmark). The dose for all antigens was 5 μg/mouse.

The experiment and care of animals was conducted in accordance with institutional guidelines to avoid unnecessary suffering.

Serology

To assess the induction of anti-HBc and anti-HBs IgG-specific antibodies at the end of the phase 1, day 34 animals’ sera were tested by an indirect EIA as reported [8]. Briefly, high binding capacity 96-well plates (Corning Life Sciences, Acton, MA) were coated with the antigen at 5 μg/mL. Plates were blocked with 2 % skim milk in PBS for 1 h at 37 °C. Subsequently, they were incubated with serum samples diluted in 1 % skim milk, and 1 % Tween 20 in PBS for 2 h at 37 °C. Rabbit-anti-mouse total IgG-specific antibodies at the end of the phase 1, day 34 animals’ sera were tested by an indirect EIA as reported [8].

The antigen CR3 was administered combined with the virus like particles of C and S proteins, respectively, with antigens immunizations and bleedings established as represented.

Figure 1. Immunization regime for evaluating the effect of pre-existing antibody responses against the hepatitis B core (C) and surface (S) antigens on the cellular immune response against the CR3 antigen. The antigen CR3 was administered combined with the virus like particles of C and S proteins, as the TERAVAC HIV-1 vaccine candidate. Two immunization phases were established (phase I and II, respectively) with antigens immunizations and bleedings established as represented.
Effect of anti-HBc and anti-HBs Abs on Teravac inoculation

At the end of the first phase of immunization, all the animals in groups 3 (HBcAg (C)) and 4 (HBcAg and HBsAg) seroconverted to HBcAg and HBsAg. As shown in figure 2, it resulted in the generation of similar high levels of anti-HBC IgG antibodies in both groups (p > 0.05, unpaired Student’s t test with Welch’s correction). Also, an important level of anti-HBs IgG antibodies was elicited in the group 4. In consequence, a pre-existing antibody response was generated in the animals. Then, in the second phase of immunization animals were further inoculated three times with Teravac, except the group 2 that was inoculated with the mixture of HBcAg and HBsAg as a negative control. Twelve days later, the proliferation of CR3(HIV)-specific CD4+ and CD8+ cells was assessed by flow cytometry. As shown in figure 3, proliferation of CD4+ cells was not abrogated by the presence of high anti-HBcAg IgG titers (see group 3) or the combination of anti-HBcAg and anti-HBsAg IgG antibodies (group 4). In fact, similar levels of proliferation was verified in both experimental groups when compared with the positive control group 1 (p > 0.05; Kruskal-Wallis and Dunn’s multiple comparisons test vs control group). When analyzing the proliferation of CD8+ cells, we noted a slightly lower average response only in group 4 in which a pre-existing anti-HBc and anti-HBs immune responses were elicited. Nevertheless, no statistically significant differences in these values could be documented when compared with the positive control group 1 (p > 0.05; Kruskal-Wallis and Dunn’s multiple comparisons test vs control group).

Our findings suggest that the CR3(HIV)-specific cellular responses of CD4+ and CD8+ cells induced by subcutaneous immunization with Teravac are not impaired by the pre-existing immune response to a single or both major structural HBV antigens. To our knowledge, this is the first report evaluating the effect of the pre-existing immune response for both VLPs of HBV on the immune response against a co-administered antigen. We did not test the effect of a pre-existing immune response to the HBsAg alone to assess the situation of vaccinated people without previous exposure to HBV. But, considering our findings...
Effect of anti-HBc and anti-HBs Abs on Teravac inoculation

Figure 3. Proliferative CD4+ and CD8+ T-cell response against the HIV-1 candidate vaccine Teravac (HIV-1 CR3 multiantigenic formulated with HBsAg (S) and HbcAg (C) virus-like particles). Balb/c mice were inoculated with the respective immunogens. Twelve days after the end of immunizations the animals were sacrificed, fresh splenocytes were labeled with carboxyfluorescein diacetate succinimidyl ester (CFSE), and cultured for 5 days with the medium, Con A and CR3 before assessing cell proliferation. Ten thousand viable lymphocytes including blasts (R1) having higher forward and side scatter than the dominant, smaller lymphocyte population were used as the gate in CD4-APC or CD8-APC versus CFSE dot plotting. The proliferative responses (Q1) were quantified by calculating the representing proliferated CD4+ or CD8+ blast cells (CD4+/ CD8+ CFSE™) as a percentage within the dividing population of lymphocytes. Data are displayed as the mean percentage of CD4+/CD8+ CFSE™cells + 95% CI from five individual mice per group.

together with those of Netter et al. [17], it suggests that such pre-existing response will not interfere in the effect attained by immunizing with Teravac.

Nevertheless, the current experimental setting has several limitations. First, the pre-existing immunity for HBV was simulated by vaccination with antigens since the mouse model does not become infected by HBV. Second, we inoculated recombinant antigens in adjuvant instead of using natural antigens recovered from patients or a whole virus lysate. Third, the pre-existing immunity was simulated for only two antigens of the HBV, not ruling out the influence of some immunopathological events associated with the HBV infection that uses the ability of hepatitis B virus surface and core antigen vaccine in patients with chronic hepatitis B. Hepatol Int. 2013;7(4):981-9.

But, it is known that the immune response to the HBsAg and HbcAg in mice resembles the human response [20]. In fact, the HBsAg is the active pharmacological antigen of prophylactic vaccines currently in use against HBV, and the in vivo potency test for the release of vaccine batches is assessed in mice because the HBsAg-specific IgG antibody response elicited in this species correlates well with the protective response in humans [21]. Therefore, despite the fact that the model used in this research did not rule out the influence of immunopathological events related to the HBV infection, it was still relevant to assess the impact of the anti-HBc and anti-HBs/anti-HBc IgG response on the CR3(HIV-1)-specific T cell response. Moreover, it could be also relevant in the case of HBV+/HIV-1+ patients. In these patients, when the nadir of CD4+ T cell counts is higher than 350 cells/µL and the HIV viral load is undetectable or very low (as under antiretroviral treatment), functional immunocompetence is preserved [22]. Thus, the findings in the mouse model are still useful to predict possible outcomes in humans vaccinated with Teravac.

The possibility to induce an anti-HIV-1 cellular response after immunization with Teravac in the presence of pre-existing immune responses to the HBV could be considered an advantage of this vaccine candidate in the therapeutic setting. In fact, there has been estimated that around 2-4 millions of HIV-infected individuals worldwide are also co-infected with HBV [23]. Moreover, it is important to consider that it is in the Subsaharan Africa where the prevalence of HBV is the highest [12] as well as for HIV-1 [23]. Taking into account the high prevalence of HBV-infected and HIV-1/HBV-coinfected patients in some geographical areas, it is important to notice that a new vaccine formulation called Nasvac is under development by our group for the treatment of chronic HBV infection, which successfully combines both the HBsAg and HbcAg antigens [24, 25]. Because the vaccine candidate Teravac comprises the same previous two antigens of the HBV plus CR3 from HIV-1, we speculate that HBV-infected and HIV-1/HBV-coinfected patients might also benefit from Teravac vaccination to achieve some control over the HBV viral load. That is important since HIV-1/HBV-coinfected is associated with lower T CD4+ counts [26].

The potential negative impact of the pre-existing anti-HBs, anti-HBC or the combined anti-HBcAg/anti-HBs IgG response on the HIV-1-specific cellular immune response elicited after inoculation with the vaccine candidate Teravac should be investigated in humans. This is paramount for HIV– individuals (prophylactic scenario) and HIV+ patients (therapeutic scenario) vaccinated against the HBV, chronically infected, convalescents or recovered from HBV infection.

Conclusions

The findings described in this study revealed no evidence that induction of CR3(HIV)-specific cellular responses of CD4+ and CD8+ cells after immunization with Teravac are impaired by pre-existing immune response to a single or both major structural antigens of HBV in mice.

Acknowledgements

This work was supported by the Center for Genetic Engineering and Biotechnology, Havana, Cuba. There are no competing financial interests. We thank Ismariley Revé, Sara Clark and Lariza Gorobaya for their technical assistance.

Received in October, 2015. Accepted in December, 2015.